Compare DuPont de Nemours Inc (DD) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs BIO-TECHNE Corp — how do they compare? DuPont de Nemours Inc trades at $131.75 (market cap $17.89B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: DuPont de Nemours Inc is the larger of the two by market cap, and DuPont de Nemours Inc pays the higher dividend (1.81%). Which is the better fit depends on your goals — on Pluang, investors hold DuPont de Nemours Inc for 89 Days and BIO-TECHNE Corp for 63 Days on average.
| DD | TECH | |
|---|---|---|
Market Cap | $17.89B | $11.36B |
Volume | 816,409 | 5,390,331 |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $72.61 |
52-Week Low | $92.49 | $43.31 |
Typical Hold Time | 89 Days | 63 Days |
Enterprise Value | $19.28B | $11.39B |
Dividend Yield | 1.81% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $131.08, down 1.65% on the day, with neutral technical signals from moving averages and oscillators. The company shows mixed fundamentals with recent earnings beats but declining revenue from $12.4B in 2024 to $6.85B in 2025, resulting in a net loss of $779M. Analyst sentiment remains positive with 58.5% buy ratings, though the consensus price target of $95 suggests caution. Recent developments include new product launches in sugar separation technology and Tyvek innovations, alongside ongoing PFAS litigation settlements.
The outlook for DD hinges on margin recovery and growth in key sectors like healthcare and water technologies, but investors face risks from legal liabilities, volatile cash flows, and high P/E valuation. Institutional activity shows mixed signals with both position reductions and significant increases, reflecting uncertainty about near-term performance amid structural growth opportunities.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
